A groundbreaking oral medication that treats diabetes and obesity while preserving vital muscle mass has successfully completed early clinical trials. The drug, called ATR-258, works differently from popular weight loss injections by targeting metabolism in skeletal muscles rather than affecting appetite or stomach emptying. “Our results point to a future where we can improve metabolic health without losing muscle mass,” says Professor Tore Bengtsson from Stockholm University, one of the researchers behind this innovation. ATR-258, developed by Swedish biotech company Atrogi in collaboration with Monash University scientists, has completed Phase 1 clinical trials. The pill works by mimicking the key … Continue reading New Oral Diabetes Therapy Mimics Exercise Effects: Treats Type 2 Diabetes While Preventing the 30% Muscle Loss Common in Weight Treatments